Peptides are legal in the US under specific conditions. A physician explains the FDA's 503A framework, which peptides are permitted, and which are not.
Peptides are legal in the US under specific conditions. A physician explains the FDA's 503A framework, which peptides are permitted, and which are not.
Are peptides legal in the United States? Peptides are legal in the United States, but their legal status depends on the specific compound, who prescribes it, and where it is prepared. Some peptides are available as physician-prescribed medications compounded by licensed pharmacies. Others sit in a regulatory grey zone or have been explicitly restricted by the FDA. There is no single answer that covers every peptide, which is why so much of the information circulating online gets this wrong.
The regulatory hinge is the FDA's 503A bulk substances framework. Under 503A, a licensed compounding pharmacy can prepare a prescription drug, including a peptide, from bulk ingredients if that substance appears on the FDA's approved bulk substances list and a physician issues a patient-specific prescription. Pharmacies operating under this framework must meet strict sterility and quality standards [1]. BPC-157, by contrast, has been explicitly named by the FDA as a substance it considers unsafe for compounding, meaning a pharmacy advertising it alongside other peptides is operating outside that framework [2].
A few practical distinctions matter most:
For a fuller picture of what physician-supervised peptide therapy actually involves, peptide therapy for men and starting peptide therapy lay out the clinical process from first consultation through first dose.
Understanding which specific peptides fall inside and outside these rules is where the real complexity begins.
The 503A pathway, created by Congress through the Drug Quality and Security Act (DQSA) of 2013, is the legal mechanism that allows a licensed compounding pharmacy to prepare a drug for a specific patient from bulk raw ingredients, provided those ingredients meet a defined set of criteria [3]. That framework is what makes physician-prescribed compounded peptides legal in the United States, and it is also what makes some peptides off-limits.
Think of 503A as a conditional permission slip. A compounding pharmacy can prepare a medication from scratch, without an FDA-approved commercial product, as long as it follows the rules of the road. Congress created 503A and its counterpart, 503B (for larger outsourcing facilities), specifically to preserve access to compounded medications while adding federal oversight after a 2012 fungal-meningitis outbreak traced to a compounding pharmacy killed dozens of people [3].
For a compounded peptide to be lawfully prepared and prescribed under 503A, it must clear three checkpoints:
The peptide's position on the bulk-substances list is the gate most patients never think to ask about, and it is the one that matters most clinically. A peptide that clears the first two gates but is prepared in a facility that skips sterility validation still poses real patient-safety risk [1].
Where a specific peptide lands on that list, and what the FDA's evaluation has concluded, determines everything about whether your prescription is lawful or not. The contrast between sermorelin and BPC-157 makes that distinction concrete, so those are worth examining closely, starting with sermorelin vs. tesamorelin.
BPC-157 is not legal for compounding in the United States right now. The FDA placed it on the Category 1 bulk substances list, which means the agency determined it presents "significant safety risks" and may not be compounded at 503A pharmacies or 503B outsourcing facilities. That is a harder stop than most peptides face.
Most peptides under regulatory review land in a gray zone while the FDA weighs evidence. BPC-157 got a definitive answer, and it went in the wrong direction for patients hoping to use it. A 2025 pilot study published in the Journal of Pharmaceutical Policy and Practice found at least one Colorado provider actively advertising compounded GLP-1 products combined with BPC-157, describing it as "a substance determined by the Food and Drug Administration to be unsafe for compounding" [2]. That characterization is the practical consequence of Category 1 status.
The pharmaceutical science behind BPC-157 helps explain why regulators hit the brakes. A 2026 narrative review in Pharmaceutics noted that BPC-157 has "no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial," and that available human data come from "fewer than 30 subjects across three uncontrolled pilot studies" [4]. A plasma half-life confirmed preclinically at under 30 minutes, combined with no validated delivery system, leaves critical safety and dosing questions unanswered [4].
If a clinic or website is selling you compounded BPC-157 injections today, they are operating outside current federal guidelines. The biology may be compelling, and preclinical data does suggest regenerative properties worth watching. The regulatory reality is still what it is. For more on what the evidence actually shows for BPC-157 and other peptides, BPC-157 peptide therapy covers the clinical picture in detail.
| Status | BPC-157 | Sermorelin |
|---|---|---|
| FDA compounding category | Category 1 (do not compound) | Compoundable at 503A pharmacies |
| Phase II human trial completed | No [4] | Yes (historical data) |
| Validated dosing regimen | No [4] | Yes |
| Prescribable through a licensed 503A pharmacy | No [2] | Yes |
Several peptides are fully accessible through a lawful, physician-supervised protocol today, but the tier they sit in determines how they reach you and what oversight applies.
The table below maps the most commonly discussed peptides to their actual regulatory status.
NOT SURE WHERE TO START?
Take our 2-minute hormone & metabolism quiz to see exactly where you stand. Or skip ahead — a $49 lab panel gives you the numbers, a free hormone screen gives you a plan.
| Peptide | Regulatory Status | How It Reaches Patients |
|---|---|---|
| Tesamorelin (Egrifta) | FDA-approved 2010 for HIV-associated lipodystrophy | Brand-name prescription; dispensed by licensed pharmacy |
| Semaglutide (Ozempic, Wegovy) | FDA-approved for type 2 diabetes and chronic weight management | Brand-name prescription; compounded versions under evolving FDA guidance |
| Tirzepatide (Mounjaro, Zepbound) | FDA-approved for type 2 diabetes and obesity | Brand-name prescription; compounded versions under evolving FDA guidance |
| Sermorelin | Compoundable at licensed 503A pharmacies; original approval withdrawn 2008 for commercial reasons, not safety | Compounded prescription from a licensed prescriber |
| CJC-1295 | Not FDA-approved; not on the 503A bulk substances permitted list | Not legally compoundable for patient use |
| Ipamorelin | Not FDA-approved; not on the 503A bulk substances permitted list | Not legally compoundable for patient use |
| PT-141 (bremelanotide) | FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women | Brand-name prescription; off-label use in men is prescriber discretion |
A 2025 cross-sectional study published in the Journal of Pharmaceutical Policy and Practice found that among 93 websites advertising compounded GLP-1 products in Colorado, multiple sites made misleading claims about regulatory approval status, and one site advertised a product compounded with BPC-157, a substance the FDA has determined is not appropriate for compounding [2].
Sermorelin occupies a more defensible position than most compounded peptides because it has decades of human use data and sits within the 503A framework. For a side-by-side breakdown of how sermorelin compares to tesamorelin in clinical practice, sermorelin vs. tesamorelin covers the key distinctions in detail.
The grey market is not a bureaucratic inconvenience. It is where patient safety breaks down in concrete, measurable ways.
Peptides sold under "research use only" labels are not manufactured to pharmaceutical standards. A 2025 analysis of compounding pharmacy raw materials found structural impurities in samples that had passed supplier qualification on paper, with Fourier Transform Infrared Spectroscopy revealing modifications that would not appear on a basic purity certificate [5]. The same contamination risk applies to any peptide sourced outside a licensed compounding pharmacy operating under USP Chapter 797, the federal sterility standard for injectable preparations [1]. When a vial bypasses that framework, there is no validated sterility test, no verified excipient compatibility, and no confirmed concentration. You may inject something labeled 5 mg that contains 2 mg, or 8 mg, or an unknown impurity.
The practical risks, stated plainly:
A 2018 review in the Journal of Drugs in Dermatology noted that the 2012 New England Compounding Center outbreak, which infected 800 people with fungal meningitis, was the direct catalyst for the tighter 503A and 503B rules that govern legitimate compounding today [3]. Unregulated peptide sourcing recreates exactly the conditions that prompted those rules.
Physician supervision is not red tape. It is the mechanism that connects a lab-verified compound to a patient with baseline bloodwork and a defined protocol. What that supervision looks like in practice is where the distinction between a compliant program and a grey-market purchase becomes most visible.
Not every patient who wants a peptide protocol should start one. A physician's job at the first visit is to separate candidates who stand to benefit clearly from those who need more caution or an outright different approach.
The strongest candidates share a recognizable profile: adults with documented symptoms, baseline lab work in hand, no active malignancy, and a willingness to monitor regularly. Growth hormone-releasing peptides, in particular, raise IGF-1 (insulin-like growth factor-1, the hormone your liver makes in response to growth hormone signals, and a key driver of tissue repair). That same IGF-1 signal that helps muscle recover can also stimulate cells that are already growing abnormally, which is why active or suspected malignancy is a firm contraindication [6].
Generally appropriate candidates:
Candidates who need extra evaluation or are not appropriate:
Understanding how to read your hormone lab report before starting any protocol makes that first physician conversation far more productive. For men with a prostate cancer history specifically, TRT after prostate cancer covers the analogous risk-stratification logic that applies equally here.
With candidacy established, the practical question becomes: what does a compliant, physician-supervised peptide program actually look like from start to finish?
A compliant, physician-supervised peptide program begins with a real clinical conversation, not an online checkout cart. Bring the following to your first appointment:
Questions to ask your prescribing clinician:
IGF-1 is worth understanding before you start. It is the clearest measurable signal that growth hormone signaling is active in your body. Research in pediatric endocrinology confirms that baseline IGF-1 standard deviation score is "among the most important indicators of GH therapy response" [7], and that monitoring it over time tracks whether a protocol is producing its intended effect [8]. The same logic applies to adults: a baseline gives your clinician a reference point; follow-up values tell you whether the therapy is doing anything.
Verification of the compounding pharmacy is not optional. Confirm the pharmacy holds 503A registration and that the specific peptide you are being prescribed is on the current 503A bulk substances list, not the FDA's list of substances it has determined are unsafe for compounding [2].
For a full walkthrough of what the process looks like from evaluation through first injection, starting peptide therapy and peptide therapy for men cover the clinical steps in detail. To speak with a clinician directly, schedule a consultation.
Peptides are legal in the US, but only under specific conditions. A licensed physician must write a patient-specific prescription, the compounding pharmacy must be registered and operating under federal sterility standards, and the specific peptide must be on the FDA's approved bulk substances list. Peptides sold online without a prescription or from unregistered sources operate outside these legal requirements, regardless of how they're labeled.
BPC-157 is not legal for compounding in the United States. The FDA placed it on the Category 1 bulk substances list, determining it presents significant safety risks and may not be compounded at licensed pharmacies. Any clinic or website selling compounded BPC-157 injections today is operating outside federal guidelines. The FDA's decision reflects that BPC-157 has no validated dosing regimen, no completed Phase II clinical trial, and human data from fewer than 30 subjects across uncontrolled studies.
Legal peptide therapy involves a physician prescription, a registered 503A pharmacy, and strict quality controls including sterility verification and dosage confirmation. Online purchases labeled research use only bypass pharmaceutical manufacturing standards entirely. Without oversight, injected peptides may contain inaccurate doses, contamination, or unknown impurities. The 2013 Drug Quality and Security Act tightened regulations after a 2012 compounding outbreak infected 800 people with fungal meningitis, making regulatory compliance a patient safety issue, not red tape.
Several peptides are legally prescribable: tesamorelin and semaglutide are FDA-approved brand-name medications, tirzepatide is FDA-approved, sermorelin is compoundable through licensed 503A pharmacies, and PT-141 is FDA-approved for specific indications. Peptides like CJC-1295 and ipamorelin are not on the FDA's approved bulk substances list and therefore cannot be legally compounded for patient use.
Ask your physician for the clinical reason the peptide is right for you, whether baseline labs will be ordered including IGF-1, whether the dispensing pharmacy is a registered 503A compounding pharmacy, what the monitoring plan looks like after starting, and how you'll know the therapy is working. Verify the pharmacy holds 503A registration and confirm your specific peptide appears on the FDA's approved bulk substances list, not its list of unsafe substances for compounding.
Take our 2-minute hormone & metabolism quiz to see exactly where you stand — or jump straight to labs or a free screen with our team.